<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00482001</url>
  </required_header>
  <id_info>
    <org_study_id>458970</org_study_id>
    <nct_id>NCT00482001</nct_id>
  </id_info>
  <brief_title>Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults</brief_title>
  <official_title>The Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to assess the role of cholinesterase inhibitors in affecting the
      driving ability of cognitively intact seniors using driving simulators. We hypothesize that
      the use of a cholinesterase inhibitor for two weeks will be associated with improvement in
      safe driving behavior on a simulated driving task.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer's disease (AD) is the most common cause of dementia, and while it is known that AD
      poses substantial risks of motor vehicle collisions, many people in the earliest stages of AD
      continue to drive. Memory problems themselves are poor predictors of who is actually unsafe
      on the road, and various medications that are used to treat people with AD may impact on
      their driving abilities. Donepezil is a drug used to treat the memory problems associated
      with AD. While previous studies have shown that it slows the decline of activities of daily
      living (eg. shopping, banking, dressing) and may improve the ability of younger pilots to
      perform on computerized flight simulators, no studies have examined the impact of donepezil
      on driving abilities in older adults.

      The present investigation is a pilot study aiming to determine if donepezil helps healthy
      older drivers perform on driving simulators. Two Canadian academic centers have different
      driving simulators - one in Toronto and one in Thunder Bay. At each of these centers, ten
      healthy men aged 65 to 75 will be randomly assigned to receive either donepezil 5mg/day or
      identical placebo for two weeks.

      Using the driving simulator, we will assess various aspects of driving ability. These
      measures of driving performance will be compared between those who received the drug and
      those who received the placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psychomotor Vigilance Test (PVT)</measure>
    <time_frame>Day 15</time_frame>
    <description>A measure of reaction time in milliseconds, using a handheld unit, in which participants respond to a visual simulus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attention Network Test (ANT)</measure>
    <time_frame>Day 15</time_frame>
    <description>A measure of reaction time in milliseconds, based on the speed with which participants press a key in response to a visual stimulus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Speed Deviation</measure>
    <time_frame>Day 15</time_frame>
    <description>A measure of deviation from posted speed limit, measured in km/h</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Deviation From Road Position</measure>
    <time_frame>Day 15</time_frame>
    <description>A measure of deviation from central road position, measured in cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reaction Time to Wind Gusts</measure>
    <time_frame>Day 15</time_frame>
    <description>Reaction time to wind gusts, measured in seconds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Time in Safe Zone</measure>
    <time_frame>Day 15</time_frame>
    <description>Time spent in safe zone (within 10km/h of speed limit and within 0.838m of centre of driving lane), measured as %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collisions</measure>
    <time_frame>Day 15</time_frame>
    <description>Number of collisions (on driving simulator)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Mental Health</condition>
  <condition>Geriatrics</condition>
  <arm_group>
    <arm_group_label>donepezil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>donepezil, capsule, 5mg daily once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (cornstarch), capsule, once daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donepezil</intervention_name>
    <arm_group_label>donepezil</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (cornstarch)</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  valid Ontario driver's license

          -  active driver (greater than or equal to three times per week)

          -  written, informed consent

          -  lives in Toronto/Thunder Bay

          -  healthy

          -  Male between 65-75 years old

        Exclusion Criteria:

          -  cognitive impairment

          -  psychiatric history

          -  sleep disorder history

          -  substance abuse

          -  neurological history

          -  medical illness

          -  ophthalmological disease

          -  psychoactive medications

          -  contra-indications to Donepezil

          -  experience car/motion sickness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Rapoport, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Bedard, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Lakehead University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathan Herrmann, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krista Lanctot, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lakehead University</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 5E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 31, 2007</study_first_submitted>
  <study_first_submitted_qc>May 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2007</study_first_posted>
  <results_first_submitted>June 22, 2017</results_first_submitted>
  <results_first_submitted_qc>February 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2019</results_first_posted>
  <last_update_submitted>February 13, 2019</last_update_submitted>
  <last_update_submitted_qc>February 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Donepezil</keyword>
  <keyword>Driving</keyword>
  <keyword>Cholinesterase Inhibitors</keyword>
  <keyword>Geriatric Psychiatry</keyword>
  <keyword>Psychopharmacology</keyword>
  <keyword>Aricept</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Donepezil</title>
          <description>donepezil: donepezil 5mg, once daily for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (cornstarch): 1 capsule daily for 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Donepezil</title>
          <description>donepezil: donepezil 5mg, once daily for 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo (cornstarch): 1 capsule daily for 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.5" spread="5.6"/>
                    <measurement group_id="B2" value="70.8" spread="4.7"/>
                    <measurement group_id="B3" value="71.7" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>number of driving days/week</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.55" spread="1.0"/>
                    <measurement group_id="B2" value="5.80" spread="1.6"/>
                    <measurement group_id="B3" value="6.18" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mini-Mental State Examination (MMSE)</title>
          <description>Mini-Mental State Examination (MMSE), range 0-30, with higher scores indicating better mental state/ cognitive performance</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.30" spread="1.1"/>
                    <measurement group_id="B2" value="29.50" spread="0.7"/>
                    <measurement group_id="B3" value="29.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Psychomotor Vigilance Test (PVT)</title>
        <description>A measure of reaction time in milliseconds, using a handheld unit, in which participants respond to a visual simulus</description>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil</title>
            <description>donepezil: donepezil 5mg, once daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (cornstarch): 1 capsule daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Psychomotor Vigilance Test (PVT)</title>
          <description>A measure of reaction time in milliseconds, using a handheld unit, in which participants respond to a visual simulus</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.62" spread="53.0"/>
                    <measurement group_id="O2" value="277.13" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Attention Network Test (ANT)</title>
        <description>A measure of reaction time in milliseconds, based on the speed with which participants press a key in response to a visual stimulus</description>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil</title>
            <description>donepezil, capsule, 5mg daily once daily for 14 days
donepezil</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo (cornstarch), capsule, once daily for 14 days
Placebo (cornstarch)</description>
          </group>
        </group_list>
        <measure>
          <title>Attention Network Test (ANT)</title>
          <description>A measure of reaction time in milliseconds, based on the speed with which participants press a key in response to a visual stimulus</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="672.37" spread="70.9"/>
                    <measurement group_id="O2" value="637.58" spread="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Speed Deviation</title>
        <description>A measure of deviation from posted speed limit, measured in km/h</description>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil</title>
            <description>donepezil: donepezil 5mg, once daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (cornstarch): 1 capsule daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Speed Deviation</title>
          <description>A measure of deviation from posted speed limit, measured in km/h</description>
          <units>kilometers / hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" spread="6.6"/>
                    <measurement group_id="O2" value="-2.41" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Deviation From Road Position</title>
        <description>A measure of deviation from central road position, measured in cm</description>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil</title>
            <description>donepezil: donepezil 5mg, once daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (cornstarch): 1 capsule daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Deviation From Road Position</title>
          <description>A measure of deviation from central road position, measured in cm</description>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.54" spread="1.1"/>
                    <measurement group_id="O2" value="26.06" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reaction Time to Wind Gusts</title>
        <description>Reaction time to wind gusts, measured in seconds</description>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil</title>
            <description>donepezil: donepezil 5mg, once daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (cornstarch): 1 capsule daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Reaction Time to Wind Gusts</title>
          <description>Reaction time to wind gusts, measured in seconds</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.5"/>
                    <measurement group_id="O2" value="1.18" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Time in Safe Zone</title>
        <description>Time spent in safe zone (within 10km/h of speed limit and within 0.838m of centre of driving lane), measured as %</description>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil</title>
            <description>donepezil: donepezil 5mg, once daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (cornstarch): 1 capsule daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time in Safe Zone</title>
          <description>Time spent in safe zone (within 10km/h of speed limit and within 0.838m of centre of driving lane), measured as %</description>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.95" spread="21.4"/>
                    <measurement group_id="O2" value="74.79" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Collisions</title>
        <description>Number of collisions (on driving simulator)</description>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil</title>
            <description>donepezil: donepezil 5mg, once daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (cornstarch): 1 capsule daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Collisions</title>
          <description>Number of collisions (on driving simulator)</description>
          <units>collisions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.7"/>
                    <measurement group_id="O2" value="0.30" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 8</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Donepezil</title>
          <description>donepezil 5mg, one capsule daily for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo (cornstarch), 1 capsule daily for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>nausea / diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>fatigue / somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>headaches / abnormal dreams</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>frequent urination</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mark Rapoport</name_or_title>
      <organization>Sunnybrook Health Sciences Centre</organization>
      <phone>416-480-4085</phone>
      <email>Mark.Rapoport@sunnybrook.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

